Abstract
Background COVID-19 pandemic has a devastating impact on the economies and health care system of sub-Saharan Africa. Healthcare workers (HWs), the main actors of the health system, are at higher-risk because of their occupation. Serology-based estimates of SARS-CoV-2 infection among HWs represent a measure of HWs’ exposure to the virus and a guide to the prevalence of SARS-CoV-2 in the community. This information is currently lacking in Ethiopia and other African countries. This study aimed to develop an in-house antibody testing assay, assess the prevalence of SARS-CoV-2 antibodies among Ethiopian high-risk frontline HWs.
Methods and findings A cross-sectional seroprevalence study was conducted among HWs in five public hospitals located in different geographic regions of Ethiopia. Socio-demographic and clinical data were collected using questionnaire-based interviews. From consenting HWs, blood samples were collected between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia. The collected sera were tested using an in-house immunoglobin G (IgG) enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 specific antibodies on sera collected from HWs. Of 1,997 HWs who provided a blood sample, demographic and clinical data, 50.5% were female, 74.0% had no symptoms compatible with COVID-19, and 29.0% had history of contact with suspected or confirmed patient with SARS-CoV-2 infection. The overall seroprevalence was 39.6%. The lowest (24.5%) and the highest (48.0%) seroprevalence rates were found in Hiwot Fana Specialized Hospital in Harar and ALERT Hospital in Addis Ababa, respectively. Of the 821 seropositive HWs, 224(27.3%) had history of symptoms consistent with COVID-19. A history of close contact with suspected/confirmed COVID-19 cases was strongly associated with seropositivity (Adjusted odds Ratio (AOR) =1.4, 95% CI 1.1-1.8; p=0.015).
Conclusion High SARS-CoV-2 seroprevalence levels were observed in the five Ethiopian hospitals. These findings highlight the significant burden of asymptomatic infection in Ethiopia, and may reflect the scale of transmission in the general population.
Why was this study done?
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global public health threat, including Africa
The actual morbidity and mortality associated with SARS-CoV-2 infection in Ethiopia underestimated due to the limited molecular testing capacity.
We have limited knowledge about the seroprevalence of COVID-19 among health workers in Ethiopia.
This study aimed to develop an in-house immunoglobin G (IgG) enzyme-linked immunosorbent assay (ELISA) for SARS-CoV-2 specific antibodies on sera collected from HWs and to find out the proportion of healthcare workers who have developed antibodies specific to SARS-CoV-2 from five public hospitals located in the different regions of Ethiopia.
What did the researchers do and find?
A cross-sectional seroprevalence study was conducted among HWs in five public hospitals located in different geographic regions of Ethiopia.
Socio-demographic and clinical data were collected from recruited and consented participants using questionnaire-based interviews.
Blood samples were collected from participants between December 2020 and February 2021, the period between the two peaks of COVID-19 in Ethiopia.
The collected sera were tested using an in-house ELISA for SARS-CoV-2 specific antibodies on sera collected from HWs.
Approximately 40% of the 1,997 healthcare workers who participated in this study had antibodies against SARS-CoV-2 infection.
No association between seropositivity and study participants’ age, gender, occupation, and comorbid medical conditions.
What do these findings mean?
The observed high seroprevalence among healthcare workers regardless of their occupation suggests the cryptic but massive SARS-CoV-2 transmission in urban hospital settings.
Most of the seropositive healthcare workers in the present study were asymptomatic, and might pose a threat to the most vulnerable populations such as individuals with comorbid medical conditions.
Given the low level of vaccine roll-out (1%), this study highlights the need to strengthen health workers’ adherence to personal protection practices such as wearing face masks to protect individuals at high risk of developing severe COVID-19 illness after SARS-CoV-2 infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This seroprevalence study was funded by Noard, and Sida core fund, and the Ethiopian Ministry of Health. Other support was obtained from the Oregon Health & Science University Innovative IDEA grant 1018784 (to FGT) and National Institutes of Health training grant T32AI747225 (to TAB). The funders had no role on the study design, execution, interpretation, or where these data were published
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Ethical review Committee of Armauer Hansen Research Institute and All African Leprosy and Tuberculosis Rehabilitation and Training Center Hospital and Institutional Review Boards of Gondar University and Arsi University while written permissions were obtained Hawasa University and Haromaya University, from Arsi University College of Health Sciences Institutional Review Board while written permissions were obtained from Hawassa University and Haromaya University. Study participation was on the voluntary basis and written informed consent was obtained from each participant.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data are included in the manuscript
